Key points are not available for this paper at this time.
PLX4032, an inhibitor of activated BRAF, has shown clinical efficacy in treating patients with melanomas carrying an activating mutation in BRAF, but resistance to the drug develops in some patients. Two recent studies show possible mechanisms of such resistance.
Solit et al. (Thu,) studied this question.